MedTrace Logo

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

NCT01866930 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 453

Last updated 2023-06-13

Study results available
· View outcomes & findings →

Summary

To evaluate Sustained Virologic Response at post treatment Week 12 (SVR12)following treatment with Lambda/RBV/DCV in chronic HCV GT-1, -2, -3 or -4 subjects co-infected with HIV-1

Conditions

  • Chronic Hepatitis C Infection

Interventions

BIOLOGICAL

Pegylated Interferon Lambda-1a

DRUG

Daclatasvir (DCV)

DRUG

Ribasphere (RBV)

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-11
Primary Completion
2015-08-27
Completion
2015-08-27

Countries

  • United States
  • Argentina
  • Belgium
  • Canada
  • France
  • Germany
  • Italy
  • Mexico
  • Poland
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01866930 on ClinicalTrials.gov